Beijing Sage Pharmaceutical Co., Ltd. announces that its products and those of its subsidiaries have been included in the 2026 National Essential Drug List. This inclusion is expected to positively impact future market expansion and sales, though short-term effects are anticipated to be minimal. Investors are advised to invest rationally and be aware of risks.
Summary generated by AI · Always verify with source document
Stock Code: 300485
Stock Abbreviation: Sage Pharmaceutical
Announcement No.: 2026-025
Beijing Sage Pharmaceutical Co., Ltd.
Announcement on Inclusion of Company and Subsidiary Products in the National Essential Drug List (2026 Edition)
The Company and the Board of Directors guarantee the truthfulness, accuracy, and completeness of the information disclosed, and that there are no false records, misleading statements, or major omissions.
Sign in to read the full translation
Free accounts get 10 full releases per month. Pro subscribers get unlimited access.